FDA Approves First Comprehensive Liquid Biopsy

Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling for patients across all solid tumors. The approval signals a shift in the treatment paradigm to one where a simple blood draw can guide treatment plans for your advanced cancer patients.

Guardant360 CDx quickly delivers the insights you need for more of your patients.

Whether at initial presentation or when your patient is no longer responding to therapy, results can help inform your patient’s treatment plan.

In 7 days, you receive test results with useful insights

- Help inform your patient’s treatment plan
- Avoid the logistical challenges and unnecessary delays associated with tissue biopsies

For the complete intended use statement and technical information document, visit Guardant360CDx.com